Fig. 3: Typical responses to apatinib treatment in two sarcoma patients.
From: Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
a, b Metastatic undifferentiated pleomorphic sarcoma lesions showed significant decrease in size and pulmonary cavities after apatinib treatment. Positron emission tomography-computed tomography (PET-CT) showed decreased tumor size, metabolic activity, pulmonary cavities, and severe pneumothorax after apatinib treatment. a Before apatinib treatment (2016.11.2). b After apatinib treatment (2017.5.19). c–f Stable lung metastatic lesion in patient with synovial sarcoma treated with apatinib. Chest CT scan showed long-term stable disease. c: CT scan before treatment (2015.12.26). d CT scan after treatment (2016.5.11). e CT scan after treatment (2016.11.23). f CT scan after treatment (2017.3.27)
